ãããâããã·ã£ã¦â¥ã祥é²ã. ã åè© ã ãã§ããé²ãç祥(ããããã)ã®é²ãçé²ã [ååºã®å®ä¾]ã祥é²æ¿æ·¡å¾¡é¸åºãçèç§å¬æäºå¸ä»ä¸ã(åºå ¸ï¼æ§ééâä¸ï¼835é ï¼å è³Â ...
ãããâããã·ã£ã¦â¥ã祥é²ã. ã åè© ã ãã§ããé²ãç祥(ããããã)ã®é²ãçé²ã [ååºã®å®ä¾]ã祥é²æ¿æ·¡å¾¡é¸åºãçèç§å¬æäºå¸ä»ä¸ã(åºå ¸ï¼æ§ééâä¸ï¼835é ï¼å è³Â ...
(BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting 10.1056/NEJMoa2101765 ) ã¤ã¹ã©ã¨ã«ã«ããã¦, 12/20-2/1ã¾ã§ã«mRNAã¯ã¯ãã³(ãã¡ã¤ã¶ã¼è£½)ãæ¥ç¨®ãã59ä¸6618人ã¨, å°å, è¨åºçèæ¯ãåãããéæ¥ç¨®ç¾¤ãæ¯è¼ãã観å¯Cohort. ã»ã¢ã¦ãã«ã ã¯ã¯ã¯ãã³æ¥ç¨®å¾14-20æ¥ä»¥å¾(2åç®æ¥ç¨®å¾ã¯7æ¥å¾)ããã®SARS-CoV-2ææç, éç, æ»äº¡ãªã¹ã¯. æ¯éå£:
æ¬åï¼è¥¿æåä¹ 1976å¹´ãç¥å¥å·ççã¾ããæ±äº¬é½ã«ç§»ããä¸å¤®å¤§å¦ã«é²å¦ãå¨å¦ä¸ã«ç±³å½ã®ã¢ã¼ã«ã³ã½ã¼å·ã«çå¦ã1999å¹´ã«ã¤ã³ã¿ã¼ãããã®å¿åæ²ç¤ºæ¿ã2ã¡ããããããéè¨ãã管ç人ã«ãªããæ±äº¬ãã©ã¹ä»£è¡¨åç· å½¹ãæªæ¥æ¤ç´¢ãã©ã¸ã«åç· å½¹ãªã©ãå¤ãã®ä¼æ¥ã«æºãããä¼ç»ç«æ¡ããµã¼ãã¹éå¶ãããã°ã©ãã¼ã¨ãã¦æ´»èºã2005å¹´ã«æ ªå¼ä¼ç¤¾ãã¯ã³ã´ã®åç· å½¹ç®¡ç人ã«å°±ä»»ãã2006å¹´ã«ããã³ãã³åç»ããéå§ã2009å¹´ã«ã2ã¡ãããããã®è²æ¸¡ãçºè¡¨ã2015å¹´ã«è±èªåæ大ã®å¿åæ²ç¤ºæ¿ã4chanãã®ç®¡ç人ã«ã主ãªèæ¸ã«ãåãæ¹ å®å ¨ç¡åãï¼å¤§åæ¸æ¿ï¼ããè«ç ´åãï¼ææ¥æ°æ¸ï¼ããç¡æµã®ç¬å¦è¡ããè«ç ´çã²ãããã®ããã°ããªãã³ãã¥è¡ãï¼ã¨ãã«å®å³¶ç¤¾ï¼ãªã©ãããã 1ï¼ ã®åªå ä¸çã®ã¤ã³ã¿ã¼ãããæ¥çã«è«å¤§ãªå½±é¿ãä¸ããç·ã西æåä¹ãè¬ã«å ã¾ããçãç«ã¡ããæèå½¢æãå¦çèµ·æ¥ããããçã§ã®æåã¾ã§ããã®äººçã縦横
ãã¼ã¿ã¼ã»ãã£ã¼ã«çãããã©ã³ãã£ã¢ã»ãã¯ããã¸ã¼ãºããã·ãªã³ã³ãã¬ã¼ã¨æ±ºå¥ããçç± 2021å¹´12æ2æ¥ ã³ã©ã ãã¤ã¦ãã¬ã¤ã»ã«ã¼ãã¯ã¤ã«ã¯ãAIã®ã¿ãªãããã¯ããã¸ã¼ã®é²åã¹ãã¼ããç¡é大ã«ãªãã人éã®è½åãæ ¹åºããè¦ãå¤å®¹ããã·ã³ã®ã¥ã©ãªãã£ãã2045å¹´ã«å°æ¥ãããã¨ãã£ãã 人å£ç¥è½ã®ä¸çç権å¨ã®ãã®æè¨ã«ãããã·ã³ã®ã¥ã©ãªãã£ã®æ¦å¿µã¯ç¬ãéã«åºãããAIå ¨çã®æ代ã«ãããä¸çã®å¨ãæ¹ã«ã¤ãã¦ä¸éã§ãçãã«è°è«ãããããã«ãªãã ã·ã³ã®ã¥ã©ãªãã£å¾ã®ä¸çãæ³åããæãã¦ã¼ããã¢ãæ³åããã®ãããã£ã¹ããã¢ãæ³åããã®ãã¯äººããããã ããæ¦ãä¼¼ããããªã·ããªãªã«å¸°çµããã ããã¯ãGAFAã®ãããªããã¯ã¸ã£ã¤ã¢ã³ããç¥ã®ä»£ç人ã®ããã«äººã ãå°ãã¨ããè¿æªæ¥ã®é¢¨æ¯ã ã ä»æ¥ããããªãã«ã¯çæ´»ãæãç«ããªããªãã»ã©äººã ã®çæ´»ã«æ·±ã浸éãã¦ããã·ãªã³ã³ãã¬ã¼ã®ãµã¼ãã¹ã®å½±é¿åãèããã°
ãã«ãã³ã»ããªã¼ããã³ã¯ã1912å¹´ãã³ã¬ãªã¼ç³»ã¦ãã¤ç§»æ°ã®åä¾ã¨ãã¦ç±³å½ã«çã¾ãã¾ãããã¨ãªã¼ãã¨ãã¦çã¾ãè²ã£ãã±ã¤ã³ãºã¨ã¯å¯¾ç§°çãªå®¶æã¨è¨ãã¾ãã ã移æ°ã®åã«ã¨ã£ã¦ãæ¿åºã¯é ãåå¨ã§ãã£ãã«éããªããé ãããå·éã«æ¿åºãè¦ã¤ããæ¿åºã¨ãããã®ã®âãããèãâãçæ¥çã«æãåã£ã¦ããã®ãããããªãã 竹ä¸å çã¯ãããåæããã¦ããã¾ããã å½¼ã¯ãã·ã«ã´å¤§å¦ã§å¦ã³ãããã¦ãã·ã«ã´å¦æ´¾ãã®ä¸å¿äººç©ã¨ãªã£ã¦ããã¾ãã ãããã¦å¥½æ¦çã§ãé ã®å転ãæ©ããå¼ãç«ã¡ãè«äºã«å¼·ãçµæ¸å¦è ã¨ãã¦ãã®åãç¥ãããã¨ããã¾ãã å½¼ãã·ã«ã´å¤§å¦ã§ãèªç±çµæ¸ã®è«è ã¨ãã¦æ´»èºãã1970年代ã¯ãä¸çä¸ãã¹ã¿ã°ãã¬ã¼ã·ã§ã³ï¼å¾è¿°ï¼ã«æ©ã¿ãã±ã¤ã³ãºæ¿çã®éçãé²åããæ代ã§ããã å½åç°ç«¯å ã¨è¨ããã¦ããããªã¼ããã³çè«ã¯ããã®æ代èæ¯ãåãã¦ä¸»æµæ´¾ã¨ãªãã80年代ã®ãµããã£ã¼ãªãºã ãã¬ã¼ã¬ããã¯ã¹ãä¸æ½æ ¹æ°æ´»è«
2021å¹´ãéã貯ããããã«ãã¹ããã¨ããéã®ãããèããå ·ä½çãªæ¹æ³ã¯ï¼ãéã貯ãããã¨æã£ã¦ãã人㸠ããã¾ãã¦ããã§ã¨ããããã¾ãã2021å¹´ã¯ã©ããªå¹´ã«ãªãã§ãããããæ°ããå¹´ã«ãªãã¨ã¯ã¯ã¯ã¯ãã¾ããã2020å¹´ã¯ã³ããã®å½±é¿ããããç°å¢ã大ããå¤ãã£ãå¹´ã§ããããªã¢ã¼ãã¯ã¼ã¯ããã£ãã·ã¥ã¬ã¹ãé²ã¿ãåãæ¹ããéã¨ã®åãåãæ¹ãå¤ããã¾ãããã¾ããã³ããã·ã§ãã¯ãããã¦ãã¤ã³ãæè³ãã¹ãã証å¸ã®èºé²ããããæè³ãå§ãã人ã大ããå¢ãã¾ããã楽天証å¸ã¯2020å¹´12æã«ã¯500ä¸å£åº§ãçªç ´ããï¼ãããã9ã«æã§100ä¸å£åº§å¢ï¼ã¨çºè¡¨ãã¾ãããå¢ããããã¾ãããä»åã¯ã2021å¹´ãéã貯ããããã«ãã¹ããã¨ããçããã¨ä¸ç·ã«èãã¦ããããã¨æãã¾ãã
å°ããªé ãããæã å¤ãªãã®ãè¦ãã ãããã¯ããããå¦æªã¨ãããããã®ã®é¡ã ç¥æ¯ã§ããã¬ã¤ã³ããã¯å¼·åãªå¦åãæã¡ãåºé¢ã£ãå¦æªã«çã£ç«¯ããåè² ãæã¿ããã³ãè² ããã¦ååã«ãªããã証ã¨ãã¦ç´ã«åãæ¸ããéããã æã¤è ã«åãå¼ã°ããã°æ±ºãã¦éãããªãå¥ç´æ¸ã®æã§ããå人帳ã éºåã¨ãã¦ãããç¶ãã§ä»¥æ¥ãå¦ã«è¥²ããããåãè¿ãããã¨ãã¦ãã¦ãã¾ãã®æ¥ã ãéããã¦ããã ã ãã©ã ãæ¤å¦ãå¦æ ¡ã§ããâ¦â¦äººã®åããããããã¾ãï¼ã ã¾ããå¦æªã¨ä¸ç·ã«å¦æ ¡ã«ç»æ ¡ããæ¥ãããã¨ã¯æã£ã¦ãããªãã£ããªã ãããå¦æ ¡ã«ã¤ããããè¿äºã¯ãã¾ãã§ããªããã ãããã£ã¦ã¾ããããåã«ãã¦ã¾ãããã ãä¿¡ãã¦ãããã³ã ãªãã§ããªãå¦æ ¡ã®æ ¡èã®ä¸ã楽ãããã«ãã¡ãã¿è¦æ¸¡ããã³ã®æãå¼ãå»ä¸ãæ©ãã éããªããå¦æ ¡ã®é¢¨æ¯ããå¦æªã§ãããã³ã«ã¯æ°é®®ã«è¦ããã®ã ãããã ããã¯ããå¤ç®ã ããã¯ããå¤ç®ããã ãã
çããä¸ããããæè²ã«éåæãè¦ããå°å¦çæ代 å¦ã³ã®ä¸çã§ãã©ãã¤ã ã·ãããå®è·µãã¦ãã人ããã¾ããããããåã©ããã¡ã«åãã¦ããèªãã®äººçãåãæãåããè²ãããã®æè²ããã°ã©ã ãæä¾ããä¼ç¤¾TimeLeap代表ã®ä»ç¦®å½©é¦ããã§ããå°å¦1å¹´çã®ã¨ãã«æ¢åã®å¦æ ¡æè²ã«çåãæ±ãããã以æ¥ãæè²ã®ããæ¹ãå¤ããã¹ã奮éãç¶ãã¦ãã¾ããç¾å¨ã®æè²ã¯ä½ãåé¡ãªã®ããèªãã®ããã·ã§ã³ã¨ãã¦ä½ãå¤ãããã¨ãã¦ããã®ããæ´»åã®åç¹ã«ãããã®ã¯ä½ãªã®ãããã®è¸ã®å ãèãã¦ã¿ã¾ããã ããã§ã¼ãã«ããä¸2ã§èµ·æ¥ãé«1ã§æ¯æ ¡ãè²·åããæ ¶æ義塾大å¦çãã¨ãã¦ã¡ãã£ã¢ã§ãæè¿ããè¦ãããããã«ãªã£ã¦ãã¾ããããã åãä½ã¨è¨ã£ã¦ãç´ æ´ãããã¨æãã®ã¯ã10代ã¨ããè¥ãã§èµ·æ¥ããã¨ããã¹ã¿ã¼æ§ãããããããèªåã®ãããããã¨ãæ確ã«æ±ãã¦ããã®ããã«å¨ãã®å¤§äººãã¡ãå·»ãè¾¼ãã§èµ·æ¥ã¨ããå½¢ã§èªå·±å®ç¾ãæãéããã¨ã
ææåæ¡å¤§ã¯âæ¿åºã®åºå£æ¦ç¥ã®å¤±æâ ââæ±äº¬ãä¸å¿ã«é½æ§è ã®æ°ãå¢ãã¦ãã¾ãããå¸ä¸ææãåºãã£ã¦ãããã¨ããè¦æ¹ãããã°ããPCRæ¤æ»ã®æ°ãå¢ãããããé½æ§è ãå¢ãããã¨ããè¦æ¹ãããã¾ããå¾³ç°å çã¯ç¾ç¶ãã©ã®ããã«æãã¦ãã¾ããï¼ å¾³ç°ãä»åã®ææåæ¡å¤§ã¯ãæ¿åºã®åºå£æ¦ç¥ã®å¤±æã§ããçµæ¸ãåéãããã¨ãã«ããæ¤æ»ã»è¿½è·¡ã»å¾ æ©ä¿è·ãã®æ¡å ã»æ´åãå¾¹åºããã«ãããªã£ãã®ããã®çç±ã§ãã ãã ãææç¶æ³ã¯ã¨ãªã¢ã«ãã£ã¦ããªãç°ãªãã¾ãããæ±äº¬ãã¨ä¸æ¬ãã«ãã¦ãå ¨ä½çã«ææãåºãã£ã¦ãããããªè¨ãæ¹ãããã¹ãã§ã¯ããã¾ãããæ°å®¿åºï¼7æ23æ¥ç¾å¨ç´¯è¨1620人ï¼ãä¸ç°è°·åºï¼å796人ï¼ã®ããã«é½æ§è ãå¤ããé½æ§çã®é«ãã¨ãªã¢ã¯ãæµè¡ãã¦ããã¨ããã¹ãã§ãããã ä¸æ¹ãåãåºå ã§ãå代ç°åºï¼å65人ï¼ãèå·åºï¼å150人ï¼ãªã©é½æ§è ãå°ãªãã¨ãªã¢ãããã¾ããã¾ãã23åºå¤ã§ã¯å «çåå¸ï¼å120
ç¹ã«å°éã¯çµã£ã¦ããªãå ç§å»ã®ããã° *å»å¦æ å ±ã®ããã°ã§ã. åå¥ã®ç¸è«ã«ã¯å¿ãããã¾ãã. ç¾å¨ã³ã¡ã³ãã®è¿äºããã¾ãããã¾ããã®ã§ã³ã¡ã³ããéãã¦ãã¾ã. ã³ã¡ã³ããããã°FBãã¼ã¸ã§ãé¡ããã¾ã (Lancet Respir Med. 2020 Feb 7. pii: S2213-2600(19)30417-5. doi: 10.1016/S2213-2600(19)30417-5. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.) ã¹ãã¤ã³ã®17 ICUã«ãããRCT. ã»ä¸ç度ï½éçARDS*ã対象ã¨ã, é常ã®ICU管ç(Lung-protective ventilationãå«ã)ã«å ãã¦Dexam
æè¿ãä»äºã«ãããæé·ãã¨ããè¨èã®æå³ãå¤ãã£ã¦ããã®ã§ã¯ãªãã ãããï¼ ã» ã» ã» äººäºãæ¡ç¨ã®çéãæ©ãã¦ããã¾ãã¨ãããããã¡ã¯ãããã«ãæé·ãã¨ããè¨èã«ã¶ã¡å½ããã¾ãã ãããã¯ãä»äºãã¨ããã¦ãæé·ãããã åã¯ããæé·ãã§ããç°å¢ãæ±ãã¦ãã¾ã ãã¡ã®ä¼ç¤¾ã¯ãäºæ¥ã¨ã¨ãã«ãæé·ãã§ãã¾ã ãã¡ã®è·å ´ã«ã¯ããæé·ãã§ããè·å ´ãå¤ãã¨æãã¾ã ã¨ããããã®ã®è¨ãæ¹ããããè³ã«ãã¾ãã ãããããèãæ¹ãã®æ¯éã¯ãã¦ããã»ã»ã»æè¿ãã¨ã¿ã«æãã¦ããã®ãããã®è¨èã«ã¾ã¤ãããæå³ã®ãºã¬ãã§ãã ãããããä¼çµ±ç大ä¼æ¥ã®äººäºæ å½è ãã¨ãè¥æã®ãã¸ãã¹ãã¼ã½ã³ãã§ã¯ãããã§ãããæé·ãã®æå³ãã絶æçãªã¾ã§ã«ããºã¬ãã¦ããã®ã§ã¯ãªãããã¨ãããã¨ãæãã¦ãã¾ãã¾ãã ããã¯ããã¼ã¿ãåå¾ããã¢ã«ãããã¯ãªè°è«ã§ã¯ããã¾ããããã ã»ã»ã»ä¼æ¥ãæ§ã ã«èãåã調æ»ããã¦ããã ãã¦æããå°è±¡ã§
人çã¯å¦ã³ã«æºã¡ã¦ãã âããããçã¾ãã¦ããåã©ããã¡ãã ãã£ã¨ç°¡åã«ä¸çä¸ã®äººãã¡ãèªç¶ã¨ã¤ãªãã社ä¼ãåµããâ ãããåãæ¥ã å¦ã³ãæè²ãç 究ããæå³ã§ãã ãã®ä¸ã«çã¾ãã¦ãã¦ããã£ãã å¿ããæãã人ã1人ã§ãå¢ããããã«ã ç¾ä»£ç¤¾ä¼ãåãå·»ãç¶æ³ã¯ã ã¾ãã¾ãè¤éåãã¦ãã¦ãã¾ãã ITãå»çæè¡ãªã©ã®æè¡é©æ°ã 人工ç¥è½ã®çºå±ã ç°å¢åé¡ã é£æ°åé¡ã å°åé«é½¢åã 社ä¼çæ ¼å·®ããªã©ãªã©ã çµæ¸ççºå±ãéãã¦ããæ¥æ¬ç¤¾ä¼ã§ã¯ããã¾ããã å¿ã®å¹³ç©ã¾ã§å«ããè±ãããå®æã§ãã¦ããªã人ãå°ãªããªãã¨æããã¾ãã ãµã³=ãã°ã¸ã¥ããªã¯ã ãçã®è´ æ²¢ã¨ãããã®ã¯ããã ä¸ã¤ãããªããããã¯äººéé¢ä¿ã¨ããè´ æ²¢ã ãã ã¨ããè¨èãæ®ãã¦ãã¾ãã 人ã¨äººãã¤ãªãããè±ç©£ãªäººéé¢ä¿ãç¯ããã¨ãããè±ããã«ã¤ãªããã®ã§ã¯ãªãã§ããããã 人ã¯çã¾ãã¦ããæ»ã¬ã¾ã§ã1人ã§ã¯çããããã 人ã¨äººã¨
ã©ã³ãã³ã°
ã©ã³ãã³ã°
ãç¥ãã
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}